FDA Clearance Tracker · P010032-S176
Proclaim SCS Neurostimulation System
Last checked: Nov 20, 2026Latest source record: Nov 17, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Nov 17, 2021
Approved
Time to decision
169 days
Received Jun 1, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P010032-S176
- Device name
- Proclaim SCS Neurostimulation System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plano, TX
- Received
- Jun 1, 2021
- Decided
- Nov 17, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P010032
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for expanded magnetic resonance (MR) Conditional labeling for the Octrode 60cm Lead when implanted with the Proclaim XR IPGs (Models 3660 and 3662) and their associated accessories, including the port plug and lead anchors. This supplement requested expansion of the conditions of use within the MRI labeling to increase radiofrequency (RF) power limit from whole body SAR <=0.8 W/kg to normal operating mode (NOM) for scans using integrated body RF transmit coil with any receive coil, and also to expand implant locations eligible for MRI scans for lead tips in epidural space from T7 to T12 to C1 to S2.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.